Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18:12:620005.
doi: 10.3389/fendo.2021.620005. eCollection 2021.

Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease

Affiliations

Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease

Amit Akirov et al. Front Endocrinol (Lausanne). .

Abstract

Background: Glucocorticoid excess in Cushing disease (CD) leads to negative feedback suppression, resulting in Crooke's hyaline change (CC) of nontumorous pituitary corticotrophs. We aimed to determine the predictive value of CC of nontumorous corticotrophs in CD.

Methods: The retrospective chart review study included patients with clinical, biochemical, radiologic and outcome data and evaluable histopathology specimens from pituitary surgery for CD. The main outcome was remission of CD, defined by clinical features, biochemical testing, and corticosteroid dependency.

Results: Of 144 CD patients, 60 (50 women, mean age 43.6±14) had clinical follow-up, biochemical data and histopathology specimens that included evaluable nontumorous adenohypophysis. Specimens from 50 patients (83.3%) demonstrated CC in nontumorous corticotrophs, and 10 (16.7%) had no CC (including 3 with corticotroph hyperplasia). One patient with CC was lost to follow-up and one without CC had equivocal outcome results. During a mean (SD) follow-up period of 74.9 months (61.0), recurrent or persistent disease was documented in 18 patients (31.0%), while 40 (69.0%) were in remission. In patients with CC, the remission rate was 73.5% (95% CI, 59.7%-83.7%) (36/49), whereas it was 44.4% (95% CI, 18.9%-73.3%) (4/9) in patients with no CC. The combination of serum cortisol >138 nmol/L within a week of surgery coupled with absence of nontumorous CC greatly improved the prediction of recurrent or persistent disease.

Conclusions: CC of nontumorous corticotrophs was observed in 83% of patients with CD, and most patients with CC experienced remission. Absence of CC in nontumorous corticotrophs may serve as a predictor of reduced remission in patients with CD.

Keywords: Crooke's changes; Cushing disease; corticotroph tumor; pituitary tumor regrowth and recurrence; pituitary tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Corticotroph Cells with Crooke’s Hyaline Changes (Bottom row) Compared with Normal Corticotrophs (Top Row). Crooke’s hyaline has a pale acidophilic appearance in slides stained with hematoxylin and eosin (H&E); the corticotrophs with this change have large clear lysosomes known as enigmatic bodies. With the periodic acid Schiff (PAS) stain, the granules of corticotrophs with Crooke’s hyaline change are found only at the cell periphery or in a juxtanuclear location. The same pattern is seen in stains for ACTH. In contrast, the hyaline material is strongly positive with the CAM 5.2 stain that localizes the keratin filaments as thick, intensely-stained bands filling the cytoplasm.
Figure 2
Figure 2
Flow diagram of exclusion criteria to arrive at the final analysis profile. The records of all patients who had pituitary surgery between January 2001 and December 2018 were screened as described in the text.

References

    1. Oldfield EH, Vance ML, Louis RG, Pledger CL, Jane JA, Jr, Lopes MS. Crooke ‘ s Changes in In Cushing‘s Syndrome Depends Susceptibility. J Clin Endocrinol Metab (2015) 100:3165–71. 10.1210/JC.2015-2493 - DOI - PubMed
    1. Asa SL, Mete O. Immunohistochemical Biomarkers in Pituitary Pathology. Endocr Pathol (2018) 29:130–6. 10.1007/s12022-018-9521-z - DOI - PubMed
    1. Asa SL, Mete O. Cytokeratin profiles in pituitary neuroendocrine tumors. Hum Pathol (2021) 107:87–95. 10.1016/j.humpath.2020.10.004 - DOI - PubMed
    1. Hague K, Post KD, Morgello S. Absence of Peritumoral Crooke ‘ s Change is Associated with Recurrence in Surgically Treated Cushing ‘ s Disease. Surg Neurol (2000) 53:77–81. 10.1016/s0090-3019(99)00159-7 - DOI - PubMed
    1. Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, et al. . Protocol for the Examination of Specimens From Patients With Primary Pituitary Tumors. Arch Pathol Lab Med (2011) 135:640–6. 10.1043/2010-0470-SAR1.1 - DOI - PubMed